Loading patent…
AssigneeCity of Hope
InventorsJavier Gordon Ogembo, Lorraine Zvichapera Mutsvunguma, David H. Mulama, Murali Muniraju, Felix Wussow
Estimating the term…
Vaccine compositions comprising a single KSHV-LP comprising two or more KSHV glycoproteins and/or one or more T cell antigens and methods of preventing or treating KSHV infections using the vaccine compositions. An expression system or a single expression vector for co-expressing two or more KSHV glycoproteins simultaneously to generate a vaccine comprising a single virus-like particle. The expression system may include a single plasmid inserted with two or more nucleic acid sequences that encode two or more KSHV glycoproteins linked by one or more linking sequences such that the KSHV glycoproteins are co-expressed simultaneously.
A multivalent Kaposi sarcoma-associated herpesvirus-like particle (KSHV-LP) comprising four KSHV glycoproteins or immunogenic fragments thereof, wherein the four KSHV glycoproteins incorporated by the multivalent KSHV-LP comprise (i) a gpK8.1 ectodomain fused to an Newcastle disease virus (NDV) structural protein sequence, (ii) a gB ectodomain fused to an NDV structural protein sequence, (iii) a gH ectodomain fused to an NDV structural protein sequence, and (iv) a full-length gL glycoprotein.
A vaccine composition or a pharmaceutical composition comprising a therapeutically effective amount of a multivalent KSHV-LP comprising four KSHV glycoproteins and one or more T cell antigens, wherein the four KSHV glycoproteins incorporated by the multivalent KSHV-LP comprise (i) a gpK8.1 ectodomain fused to an NDV structural protein sequence, (ii) a gB ectodomain fused to an NDV structural protein sequence, (iii) a gH ectodomain fused to an NDV structural protein sequence, and (iv) a full-length gL glycoprotein.
An expression system for co-expressing four KSHV envelope glycoproteins including a multivalent vector inserted with four nucleic acid sequences that encode four KSHV envelope glycoproteins, linked by one or more linking sequences, such that the four KSHV envelope glycoproteins can be co-expressed simultaneously, self-cleaved and/or self-processed to assemble into one or more glycoprotein complexes, wherein the four KSHV envelope glycoproteins incorporated by the multivalent KSHV-LP comprise (i) a gpK8.1 ectodomain fused to an Newcastle disease virus (NDV) structural protein sequence, (ii) a gB ectodomain fused to an NDV structural protein sequence, (iii) a gH ectodomain fused to an NDV structural protein sequence, and (iv) a full-length gL glycoprotein.
Dependencies are inferred from the claim text.